Cognito Therapeutics raises $35M Series B extension
PRIVATEJan 30, 2024
Amount Raised
$35 Million
Round Type
Series B
CambridgeManufacturingHealthcareHealth Care
Investors
WsgrStarbloomIag CapitalAlzheimer’s Drug Discovery FoundationMorningsideFounders X
Description
Cognito Therapeutics raised a $35 million Series B extension round, bringing the total round to $108 million and its total funding to $128 million. The funding will be used to support the HOPE study for the treatment of Alzheimer’s, as well as the continued expansion and protection of its IP position in gamma frequency therapy. It will also be used to support its Ph2 studies in Multiple Sclerosis and Parkinson’s Disease.
Who to call at Cognito Therapeutics, and when
A new round usually means Cognito Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Cognito Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Cognito Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Cognito Therapeutics
Location
55 CAMBRIDGE PKWY
Cambridge, Massachusetts, United States
About
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cognito Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeManufacturingHealthcareHealth Care